Skip to content
HowShorted

Altimmune, Inc. short interest in 2023

In 2023, Altimmune, Inc.'s disclosed short interest ran from 14.89% of shares outstanding on 13 Jan 2023 to 17.57% on 29 Dec 2023, a change of +2.68 percentage points. The year's high was 20.65% on 15 Dec 2023 and its low 10.98% on 15 Aug 2023, averaging 15.02% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.00 days on 29 Sep 2023. Full history: Altimmune, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Altimmune, Inc. in 2023

2023 in figures

Start of year
14.89% (13 Jan 2023)
End of year
17.57% (29 Dec 2023)
Change
+2.68 pp
High
20.65% (15 Dec 2023)
Low
10.98% (15 Aug 2023)
Average
15.02%
Highest days to cover
8.00 (29 Sep 2023)
SEC filings marked
8

Every report in 2023

Altimmune, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202314.89%6.52
31 Jan 202312.56%3.95
15 Feb 202312.74%5.97
28 Feb 202312.94%6.8910-K filed, results (8-K)
15 Mar 202315.02%6.02
31 Mar 202319.27%2.01
14 Apr 202320.01%4.84
28 Apr 202318.34%5.07
15 May 202317.96%6.9710-Q filed, results (8-K)
31 May 202318.42%6.36
15 Jun 202318.52%5.64
30 Jun 202314.12%1.70
14 Jul 202314.92%5.63
31 Jul 202312.49%5.00
15 Aug 202310.98%4.1810-Q filed, results (8-K)
31 Aug 202311.45%7.64
15 Sep 202312.41%5.65
29 Sep 202313.57%8.00
13 Oct 202314.05%6.79
31 Oct 202313.02%4.63
15 Nov 202312.52%5.1810-Q filed, results (8-K)
30 Nov 202312.00%3.86
15 Dec 202320.65%1.00
29 Dec 202317.57%1.00

See also: Altimmune, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.